K. R. Flaherty, K. K. Brown, and A. U. Wells, Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease, BMJ Open Respir Res, vol.4, p.212, 2017.

T. A. Mikolasch and J. C. Porter, Transbronchial cryobiopsy in the diagnosis of interstitial lung disease: a cool new approach, Respirology, vol.19, pp.623-624, 2014.

L. Richeldi, H. R. Collard, and M. G. Jones, Idiopathic pulmonary fibrosis, Lancet, vol.389, pp.1941-1952, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01600144

V. Cottinn, N. A. Hirani, and D. L. Hotchkin, Presentation, diagnosis and clinical course of the spectrum of progressive fibrosing interstitial lung diseases, Eur Respir Rev, vol.26, p.180076, 2017.

W. D. Travis, U. Costabel, and D. M. Hansell, An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias, Am J Respir Crit Care Med, vol.188, pp.733-748, 2013.

G. Raghu, B. Rochwerg, and Y. Zhang, An Official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline, Am J Respir Crit Care Med, vol.192, pp.3-19, 2015.

J. London, A. El-ghaz, and S. , Pilot study of pirfenidone in pulmonary fibrosis with anti-myeloperoxydase antibodies (PIRFENIVAS), 2018.

A. European-medicines, Esbriet® Summary of Product Characteristics, 2018.

L. Richeldi, V. Cottin, and R. M. Bois, Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS((R)) trials, Respir Med, vol.113, pp.74-79, 2016.

G. Raghu, H. R. Collard, and J. J. Egan, An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management, Am J Respir Crit Care Med, vol.183, pp.788-824, 2011.

G. Raghu and L. Richeldi, Current approaches to the management of idiopathic pulmonary fibrosis, Respir Med, vol.129, pp.24-30, 2017.

T. Scullion, P. Gorman, and E. Gibson, Antifibrotic therapy in idiopathic pulmonary fibrosis, Ulster Med J, vol.86, p.73, 2017.


L. Richeldi, U. Costabel, and M. Selman, Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis, N Engl J Med, vol.365, pp.1079-1087, 2011.

L. Richeldi, R. M. Bois, and G. Raghu, Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis, N Engl J Med, vol.370, pp.2071-2082, 2014.

T. E. King, W. Z. Bradford, and S. Castro-bernardini, A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, N Engl J Med, vol.370, pp.2083-2092, 2014.

F. Hilberg, G. J. Roth, and M. Krssak, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy, Cancer Res, vol.68, pp.4774-4782, 2008.

L. Wollin, E. Wex, and A. Pautsch, Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis, Eur Respir J, vol.45, pp.1434-1445, 2015.

G. J. Roth, R. Binder, and F. Colbatzky, Nintedanib: from discovery to the clinic, J Med Chem, vol.58, pp.1053-1063, 2015.

L. Wollin, A. Ostermann, and C. Williams, Nintedanib inhibits pro-fibrotic mediators from T cells with relevance to connective tissue disease-associated interstitial lung disease, Eur Respir J, vol.50, p.903, 2017.

F. Varone, G. Sgalla, and B. Iovene, Nintedanib for the treatment of idiopathic pulmonary fibrosis, Expert Opin Pharmacother, vol.19, pp.167-175, 2018.

, European Medicines Agency. Science Medicines Health. OFEV® (nintedanib, 2017.

R. P. Baughman and R. Reeves, Pirfenidone for Progressive Fibrotic Sarcoidosis (PirFS), 2017.

J. Macias-barragan, A. Sandoval-rodriguez, and J. Navarro-partida, The multifaceted role of pirfenidone and its novel targets, Fibrogenesis Tissue Repair, vol.3, p.16, 2010.

A. U. Wells, K. K. Brown, and K. R. Flaherty, What's in a name? That which we call IPF, by any other name would act the same, Eur Respir J, vol.51, p.1800692, 2018.

. Roche, Esbriet® US prescribing information, 2017.

, Esbriet® ( pirfenidone) authorisation details, European Medicines Agency. Science Medicines Health, 2018.

P. W. Noble, C. Albera, and W. Z. Bradford, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, Lancet, vol.377, pp.1760-1769, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00873255

. Shionogi-&-co and . Ltd, Pharmaceuticals and Medical Devices Agency, Japan. Pirespa® ( pirfenidone) authorisation details. www.pmda.go.jp/files/000153687.pdf. Date last updated: Sept 16, 2008.

B. W. Kinder, C. Shariat, and H. R. Collard, Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function, Lung, vol.188, pp.143-149, 2010.

H. Nunes, K. Schubel, and D. Piver, Nonspecific interstitial pneumonia: survival is influenced by the underlying cause, Eur Respir J, vol.45, pp.746-755, 2015.

W. D. Travis, G. Hunninghake, T. E. King, and . Jr, Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project, Am J Respir Crit Care Med, vol.177, pp.1338-1347, 2008.

H. Yamakawa, H. Kitamura, and T. Takemura, Prognostic factors and disease behaviour of pathologically proven fibrotic non-specific interstitial pneumonia, Respirology, vol.23, pp.1032-1040, 2018.

Y. Kondoh, H. Taniguchi, and T. Yokoi, Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia, Eur Respir J, vol.25, pp.528-533, 2005.

S. Tomassetti, J. H. Ryu, and S. Piciucchi, Nonspecific interstitial pneumonia: what is the optimal approach to management?, Semin Respir Crit Care Med, vol.37, pp.378-394, 2016.

S. H. Lee, M. S. Park, and S. Y. Kim, Factors affecting treatment outcome in patients with idiopathic nonspecific interstitial pneumonia: a nationwide cohort study, Respir Res, vol.18, p.204, 2017.

T. J. Corte, R. Ellis, and E. A. Renzoni, Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia, Sarcoidosis Vasc Diffuse Lung Dis, vol.26, pp.132-138, 2009.

C. J. Ryerson, T. H. Urbania, and L. Richeldi, Prevalence and prognosis of unclassifiable interstitial lung disease, Eur Respir J, vol.42, pp.750-757, 2013.

Y. Nakamura, K. Sugino, and M. Kitani, Clinico-radio-pathological characteristics of unclassifiable idiopathic interstitial pneumonias, Respir Investig, vol.56, pp.40-47, 2018.

, European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, Am J Respir Crit Care Med, vol.165, pp.277-304, 2002.

J. Bluett, M. Jani, and D. Symmons, Practical management of respiratory comorbidities in patients with rheumatoid arthritis, Rheumatol Ther, vol.4, pp.309-332, 2017.

K. Iqbal and C. Kelly, Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review, Ther Adv Musculoskelet Dis, vol.7, pp.247-267, 2015.

M. Shaw, B. F. Collins, and L. A. Ho, Rheumatoid arthritis-associated lung disease, Eur Respir Rev, vol.24, pp.1-16, 2015.

M. Yusof, M. Y. Kabia, A. Darby, and M. , Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre, Rheumatology (Oxford), vol.56, pp.1348-1357, 2017.

C. Fernandez-diaz, J. Loricera, and S. Castaneda, Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients, Semin Arthritis Rheum, vol.48, pp.22-27, 2018.

I. Rosas, Phase ll study of pirfenidone in patients with RAILD, 2017.

K. C. Silver and R. M. Silver, Management of systemic-sclerosis-associated interstitial lung disease, Rheum Dis Clin North Am, vol.41, pp.439-457, 2015.

D. P. Tashkin, R. Elashoff, and P. J. Clements, Cyclophosphamide versus placebo in scleroderma lung disease, N Engl J Med, vol.354, pp.2655-2666, 2006.

D. P. Tashkin, R. Elashoff, and P. J. Clements, Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease, Am J Respir Crit Care Med, vol.176, pp.1026-1034, 2007.

D. S. Domiciano, E. Bonfa, and C. T. Borges, A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma, Clin Rheumatol, vol.30, pp.223-229, 2011.


A. Fischer, K. K. Brown, D. Bois, and R. M. , Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease, J Rheumatol, vol.40, pp.640-646, 2013.

A. Tzouvelekis, N. Galanopoulos, and E. Bouros, Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis, Pulm Med, vol.2012, p.143637, 2012.

D. P. Tashkin, M. D. Roth, and P. J. Clements, Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial, Lancet Respir Med, vol.4, pp.708-719, 2016.

D. Daoussis, S. N. Liossis, and A. C. Tsamandas, Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study, Rheumatology (Oxford), vol.49, pp.271-280, 2010.

S. Jordan, J. H. Distler, and B. Maurer, Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group, Ann Rheum Dis, vol.74, pp.1188-1194, 2015.

C. Sharp, M. Mccabe, and N. Dodds, Rituximab in autoimmune connective tissue disease-associated interstitial lung disease, Rheumatology (Oxford), vol.55, pp.1318-1324, 2016.

D. Daoussis, S. N. Liossis, and A. C. Tsamandas, Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis, Clin Exp Rheumatol, vol.30, pp.17-22, 2012.

T. Maher, Rituximab versus cyclophosphamide in connective tissue disease-ILD (RECITAL), 2017.

D. Khanna, C. Albera, and A. Fischer, An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial, J Rheumatol, vol.43, pp.1672-1679, 2016.

M. Kreuter, A. Olson, and A. Fischer, Current treatment of patients with non-IPF progressive fibrosing interstitial lung disease, Am J Respir Crit Care Med, vol.197, p.4273, 2018.

Y. Miura, T. Saito, and K. Fujita, Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease, Sarcoidosis Vasc Diffuse Lung Dis, vol.31, pp.235-238, 2014.

M. Binks, J. R. Passweg, and D. Furst, Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease, Ann Rheum Dis, vol.60, pp.577-584, 2001.

D. Farge, J. Passweg, and J. M. Van-laar, Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry, Ann Rheum Dis, vol.63, pp.974-981, 2004.

R. A. Nash, P. A. Mcsweeney, and L. J. Crofford, High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study, Blood, vol.110, pp.1388-1396, 2007.

R. K. Burt, S. J. Shah, and K. Dill, Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial, Lancet, vol.378, pp.498-506, 2011.

J. M. Van-laar, K. Naraghi, and A. Tyndall, Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis, Rheumatology (Oxford), vol.54, pp.2126-2133, 2015.

A. Suzuki, Y. Kondoh, and A. Fischer, Recent advances in connective tissue disease related interstitial lung disease, Expert Rev Respir Med, vol.11, pp.591-603, 2017.

J. M. Van-laar, D. Farge, and J. K. Sont, Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial, JAMA, vol.311, pp.2490-2498, 2014.

K. M. Sullivan, E. A. Goldmuntz, and L. Keyes-elstein, Myeloablative autologous stem-cell transplantation for severe scleroderma, N Engl J Med, vol.378, pp.35-47, 2018.

J. Andrade, M. Schwarz, and H. R. Collard, The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes, Chest, vol.148, pp.1034-1042, 2015.

F. Perez, E. R. Swigris, J. J. Forssen, and A. V. , Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis, Chest, vol.144, pp.1644-1651, 2013.

G. Raghu, Interstitial lung disease, 2016.

Y. Miyazaki, T. Tsutsui, and N. Inase, Treatment and monitoring of hypersensitivity pneumonitis, Expert Rev Clin Immunol, vol.12, pp.953-962, 2016.

A. Adegunsoye, J. M. Oldham, F. Perez, and E. R. , Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis, ERJ Open Res, vol.3, pp.16-02017, 2017.

J. Morisset, K. A. Johannson, and E. Vittinghoff, Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis, Chest, vol.151, pp.619-625, 2017.

D. Valeyre, A. Prasse, and H. Nunes, Lancet, vol.383, pp.1155-1167, 2014.

S. G. West, Current management of sarcoidosis I: pulmonary, cardiac, and neurologic manifestations, Curr Opin Rheumatol, vol.30, pp.243-248, 2018.

R. P. Baughman and E. E. Lower, Leflunomide for chronic sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, vol.21, pp.43-48, 2004.

D. H. Sahoo, D. Bandyopadhyay, and M. Xu, Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis, Eur Respir J, vol.38, pp.1145-1150, 2011.

P. Korsten, K. Strohmayer, and R. P. Baughman, Refractory pulmonary sarcoidosis -proposal of a definition and recommendations for the diagnostic and therapeutic approach, Clin Pulm Med, vol.23, pp.67-75, 2016.

A. Vorselaars, W. A. Wuyts, and V. Vorselaars, Methotrexate vs azathioprine in second-line therapy of sarcoidosis, Chest, vol.144, pp.805-812, 2013.

A. K. Brill, S. R. Ott, and T. Geiser, Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study, Respiration, vol.86, pp.376-383, 2013.

N. Hamzeh, A. Voelker, and A. Forssen, Efficacy of mycophenolate mofetil in sarcoidosis, Respir Med, vol.108, pp.1663-1669, 2014.

R. P. Baughman, M. Drent, and M. Kavuru, Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement, Am J Respir Crit Care Med, vol.174, pp.795-802, 2006.

K. C. Patterson and M. E. Strek, Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes, Ann Am Thorac Soc, vol.10, pp.362-370, 2013.


C. Beer, H. A. Kolstad, and K. Sondergaard, A systematic review of occupational exposure to coal dust and the risk of interstitial lung diseases, Eur Clin Respir J, vol.4, p.1264711, 2017.

J. L. Perret, B. Plush, and P. Lachapelle, Coal mine dust lung disease in the modern era, Respirology, vol.22, pp.662-670, 2017.

M. Kreuter, J. Walscher, and J. Behr, Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?), Curr Opin Pulm Med, vol.23, pp.418-425, 2017.

J. J. Solomon, A. L. Olson, and A. Fischer, Scleroderma lung disease, Eur Respir Rev, vol.22, pp.6-19, 2013.

E. L. Herzog, A. Mathur, and A. M. Tager, Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?, Arthritis Rheumatol, vol.66, pp.1967-1978, 2014.

, A trial to compare nintedanib with placebo for patients with scleroderma-related lung fibrosis, 2018.

O. Distler, K. K. Brown, and J. Distler, Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS), Clin Exp Rheumatol, vol.35, pp.75-81, 2017.

, Efficacy and safety of nintedanib in patients with progressive fibrosing interstitial lung disease, 2018.

O. Brugière, Nintedanib in lung transplant recipients with bronchiolitis obliterans syndrome grade 1-2 (INFINITx-BOS, 2018.

J. Behr, P. Neuser, and A. Prasse, Exploring efficacy and safety of oral pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) -a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial, BMC Pulm Med, vol.17, p.122, 2017.

K. Fier, Study of efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis, 2017.

P. Pena, 97 A study of pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease, Pirfenidone in the chronic hypersensitivity pneumonitis treatment (Picheon, 2015.

S. Ye, Pirfenidone in progressive interstitial lung disease associated with clinically amyopathic dermatomyositis, 2016.

M. Perch, Date last accessed, BOS, a European multi-center study, 2016.

M. Roth, Scleroderma Lung Study III -Combining Pirfenidone With Mycophenolate (SLSIII). https:// clinicaltrials.gov/ct2/show/NCT03221257 Date last updated: Sept 10, 2018.

L. Wollin, I. Maillet, and V. Quesniaux, Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis, J Pharmacol Exp Ther, vol.349, pp.209-220, 2014.

J. Huang, C. Beyer, and K. Palumbo-zerr, Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis, Ann Rheum Dis, vol.75, pp.883-890, 2016.